ARS Pharmaceuticals, Inc. SPRY Enterprise value

Enterprise value at other companies

Aquestive Therapeutics, Inc.AQST

$460.11M+65.5%

Amneal Pharmaceuticals, Inc.AMRX

$7.97B+71.3%

ViatrisVTRS

$31.23B+26.4%

AMP

Amphastar PharmaceuticalsAMPH

$1.35B-16.7%

Neuropace, Inc.NPCE

$497.55M+11.5%

Eton Pharmaceuticals, Inc.ETON

$684.98M+89.8%

FAQ

What is ARS Pharmaceuticals, Inc.'s enterprise value?

ARS Pharmaceuticals, Inc. (SPRY) reported enterprise value of $869.56M in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s enterprise value changed year-over-year?

ARS Pharmaceuticals, Inc.'s enterprise value decreased by 27.2% year-over-year, from $1.19B to $869.56M.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s enterprise value?

Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s enterprise value has grown at a -0.3% compound annual growth rate (CAGR), from $1.22B to $1.21B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.